Intermittent Ropivacaine Bolus for Epidural Labor Analgesia

• Status: Completed
• Trial end date: 2019-07-04
• Target enrollment: 0
• Participant gender: Female

Summary

Enhanced patient safety and satisfaction have contributed to growing use of epidural labor analgesia. Epidural analgesia appears to be currently the most effective technique in reducing pain during labor. However, reduction in total dose of local anesthetic and thus motor blockade is crucial to improve the obstetric outcome. This technique has evolved from intermittent boluses by anesthesiologists to the current standard labor epidural analgesic regimens in many institutions in North America and Europe that consist of a local anesthetic in combination with an opioid delivered via continuous epidural infusion (CEI) with or without patient-controlled epidural analgesia (PCEA) boluses. Recently,a new mode of administration has been used: regular bolus of low concentration local anesthetic + intermittent bolus (PIEB). This technique would offer safe and superior quality labor analgesia and greater maternal satisfaction by reducing total amount of the drug combination.

The primary outcome was to evaluate the analgesic efficacy of PIEB epidural drug delivery in terms of visual analogue scale satisfaction (VAS) score in a large cohort of patients. The secondary outcomes were to measure the degree of motor blockade, neonatal and obstetric outcomes, total drug dose and incidence of pain that required top-up administration (breakthrough pain)

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pierre and Marie Curie University
• Treatments: Ropivacaine

Criteria

Inclusion Criteria:

• healthy term primi or second gravid parturients

• aged 18-30 years

• singleton, live fetus

• vertex presentation

• active stage of labor with cervical dilation of 3-5 cm parturients

Exclusion Criteria:

• Hypertension

• no vertex presentation

• contraindications to neuraxial blockade